Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Purpura, Thrombocytopenic, Idiopathic

imatinib mesylate has been researched along with Purpura, Thrombocytopenic, Idiopathic in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's0 (0.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Autore, F; Chiusolo, P; Colangelo, M; Minnella, G; Rossi, E; Sica, S; Sora', F1
Itoh, Y; Nakamura, Y; Wakimoto, N1
Hibi, S; Imashuku, S; Kano, G; Kuriyama, K; Morimoto, A; Todo, S1
Hellmann, A; Knopińska-Posłuszny, W; Langowska, B; Mikołajczuk, J; Prejzner, W1
Arima, N; Arimura, K; Ayukawa, T; Kukita, T; Kuroki, T; Matsushita, K; Ohtsubo, H; Tei, C1
Digumarti, R; Paul, TR; Rajappa, S; Varadpande, L1

Other Studies

6 other study(ies) available for imatinib mesylate and Purpura, Thrombocytopenic, Idiopathic

ArticleYear
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
    Medicina (Kaunas, Lithuania), 2021, Dec-03, Volume: 57, Issue:12

    Topics: Benzoates; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles

2021
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
    International journal of hematology, 2023, Volume: 117, Issue:4

    Topics: Adrenal Cortex Hormones; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prednisolone; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia

2023
Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
    Medical and pediatric oncology, 2003, Volume: 41, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines

2003
Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571.
    Clinical and laboratory haematology, 2003, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Colony-Forming Units Assay; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines

2003
Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia.
    Acta haematologica, 2004, Volume: 112, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Remission Induction

2004
Imatinib mesylate induced immune thrombocytopenia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:11

    Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines

2007